Northwest Investment Counselors LLC grew its stake in Johnson & Johnson (NYSE:JNJ) by 3.2% during the third quarter, HoldingsChannel reports. The fund owned 35,874 shares of the company’s stock after purchasing an additional 1,119 shares during the quarter. Johnson & Johnson makes up 2.0% of Northwest Investment Counselors LLC’s investment portfolio, making the stock its 6th biggest position. Northwest Investment Counselors LLC’s holdings in Johnson & Johnson were worth $4,664,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. Harding Loevner LP bought a new position in shares of Johnson & Johnson during the second quarter valued at approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. boosted its stake in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares in the last quarter. IHT Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after purchasing an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc bought a new position in shares of Johnson & Johnson during the second quarter valued at approximately $124,000. Institutional investors and hedge funds own 65.71% of the company’s stock.
Several equities research analysts have weighed in on JNJ shares. Wells Fargo & Co restated an “outperform” rating and issued a $160.00 target price (up from $155.00) on shares of Johnson & Johnson in a research note on Friday, January 12th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 target price for the company in a research note on Thursday, January 11th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. Citigroup raised their target price on shares of Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research note on Monday, October 23rd. Finally, Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus target price of $145.94.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the company posted $1.68 earnings per share. sell-side analysts expect that Johnson & Johnson will post 7.28 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.29%. Johnson & Johnson’s dividend payout ratio is currently 58.33%.
ILLEGAL ACTIVITY NOTICE: This piece was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3144047/johnson-johnson-jnj-shares-bought-by-northwest-investment-counselors-llc.html.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.